TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2

Eur Cytokine Netw. 1990 Oct-Nov;1(4):221-7.

Abstract

In this study we analyzed the induction of NK and LAK cell functions by TNF alpha, alone or combined with IL-2, in 4 days in vitro culture of PBMC from patients treated with alpha IFN + IL-2. Although the MN cell recovery after 4 days culture was very similar with TNF alpha alone or with IL-2 alone, TNF alpha did not maintain nor induce LAK or NK activities of in vivo preactivated PBMC. When compared to preculture values, TNF alpha alone induced a preferential outgrowth of CD4+ T cells together with a decrease of CD8+ T cells, NK cells and IL-2R (p55)-expressing cells. The combination of TNF alpha (100 ng) and high dose IL-2 (9,000 IUg/ml) did not improve the MN cell recovery after 4 days culture; but increased IL-2-induced NK activities in PBMC from 6/7 patients, and IL-2-induced LAK activities in 4/7 patients. However, these variations were not significant. The combination of TNF alpha and lower doses of IL-2, ranging from 150 IU/ml to 30 IU/ml, did not modify MN cell recovery in culture nor IL-2-induced NK and LAK cell activities. When compared to paired samples cultured with IL-2 alone, the combination of TNF alpha with all doses of IL-2 did not modify the distribution of T and NK cells, but increased the expression of CD8 on NK cells. Furthermore, the combination of TNF alpha and IL-2 increased the expression of IL-2R (p55) on PBMC but the expression of this receptor was restricted to CD4+ T cells and did not appear on NK cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / analysis
  • Carcinoma, Renal Cell / immunology*
  • Carcinoma, Renal Cell / therapy
  • Cell Division / drug effects
  • Cells, Cultured
  • Humans
  • Immunity, Cellular / drug effects
  • Immunologic Factors / therapeutic use
  • Interleukin-2 / pharmacology*
  • Interleukin-2 / therapeutic use
  • Kidney Neoplasms / immunology*
  • Kidney Neoplasms / therapy
  • Killer Cells, Lymphokine-Activated / drug effects*
  • Killer Cells, Natural / drug effects*
  • Leukocytes, Mononuclear / drug effects*
  • Leukocytes, Mononuclear / immunology
  • Lymphocyte Activation / drug effects
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use
  • T-Lymphocyte Subsets / drug effects
  • T-Lymphocyte Subsets / immunology
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • Antigens, CD
  • Immunologic Factors
  • Interleukin-2
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha